Author

Pingfu Fu

Institution: Case Western Reserve University

Observed institution: Case Western Reserve University

ORCID: 0000-0002-2334-5218

Observed ORCID: 0000-0002-2334-5218

OpenAlex ID: A5134096552

Spatial transcriptomics-guided pathology biomarker as a predictor of benefit of adjuvant docetaxel in high-risk localized prostate cancer: NRG/RTOG 0521 (NCT00288080).

2026 · Md Mamunur Rahaman, Amritpal Singh, et al. · Journal of Clinical Oncology · 1

Spatial transcriptomics–guided computational pathology model to stratify docetaxel benefit in metastatic hormone-sensitive prostate cancer: CHAARTED trial (ECOG-ACRIN E3805).

2026 · Md Mamunur Rahaman, Sebastian R. Medina, et al. · Journal of Clinical Oncology · 1

Neoadjuvant Adaptive Pazopanib With Concurrent Fixed-Dose Radiation in Localized Soft-Tissue Sarcoma

2026 · Rohit Rao, Felicia Tejawinata, et al. · American Journal of Clinical Oncology

CardioMorph Atlas: a statistical approach to evaluate association between pulmonary tuberculosis and cardiac morphology from chest X-rays

2026 · Amritpal Singh, Sena Azamat, et al. · EBioMedicine

Baseline CT-derived QVT score as predictor of bevacizumab benefit in advanced non-squamous NSCLC: A retrospective biomarker analysis of SWOG S0819.

2026 · Kai Zhang, Pushkar Mutha, et al. · Journal of Clinical Oncology

A phase II trial of trifluridine/tipiracil plus oxaliplatin in patients with advanced or metastatic biliary tract cancer following first-line therapy.

2026 · Madison Conces, Bassam N. Estfan, et al. · Journal of Clinical Oncology

An AI-based pathology classifier to predict benefit from enzalutamide in metastatic hormone-sensitive prostate cancer (mHSPC) from ENZAMET (ANZUP 1304).

2026 · Sebastian R. Medina, Naoto Tokuyama, et al. · Journal of Clinical Oncology

Risk and patterns of recurrence for patients (pts) with advanced urothelial carcinoma (aUC) metastatic to liver after response to enfortumab vedotin + pembrolizumab (EVP).

2026 · Rishi Raju Patel, Cindy Y. Jiang, et al. · Journal of Clinical Oncology

Effect of on-treatment dose adjustments on the efficacy of enfortumab vedotin and pembrolizumab (EVP) in advanced urothelial carcinoma (aUC): A UNITE analysis.

2026 · Jeffrey Yinhong Zhong, Albert Jang, et al. · Journal of Clinical Oncology

Abstract 5069: Ethnic differences in the immune landscape and gene signature in prostate cancer

2026 · Shiv S. Verma, Pingfu Fu, et al. · Cancer Research

Variant allele frequency as a potential marker in response to frontline systemic therapy for patients with locally advanced and metastatic urothelial carcinoma

2026 · Albert Jang, Sulin Wu, et al. · Translational Andrology and Urology

Computationally Derived Spatial Immune Signature Identifies Trastuzumab Responders in HER2+ Breast Cancer: NSABP B-41 Clinical Trial Validation

2026 · Satvika Bharadwaj, Germán Corredor, et al. · Clinical Cancer Research

Effect of upfront dose reductions on efficacy of enfortumab vedotin and pembrolizumab (EVP) in advanced urothelial carcinoma (aUC): A UNITE analysis.

2026 · Jeffrey Yinhong Zhong, Albert Jang, et al. · Journal of Clinical Oncology

Works count: 13

Citation count: 2

H-index: 1

I10-index: